Economic strength has increased significantly, and more and more pharmaceutical companies have begun to try international exploration

From the perspective of the country's overall development trend and industry development stage, internationalization is almost a must for the domestic pharmaceutical industry.

Take Hengrui Medicine as an example.
Over the years, the company has adhered to its international development strategy, accelerated the overseas clinical exploration of innovative drugs, actively exported innovative drug achievements overseas, and continued to expand its innovative territory overseas.
In recent years, Hengrui has established R&D centers in New Jersey, Boston, and Nagoya, Japan.
Last year, Hengrui Medicine also invested in the establishment of a clinical center in Basel, Switzerland, to improve its R&D layout in Europe and create conditions for innovative drugs to enter the global market.

Now Hengrui Medicine has 20 preparation products such as injections, oral preparations and inhalation anesthetics on the market in Europe, America and Japan, becoming a Chinese pharmaceutical company that realizes the large-scale sales of injections in Europe, America and Japan.
Its innovative drug research results have been frequently recognized internationally, marking the rapid development of the company's internationalization process.

In addition to Hengrui Pharmaceuticals, Fosun Pharmaceuticals is also one of the domestic pharmaceutical companies that explored international cooperation earlier.
It is reported that it has a unique vision in terms of introduction, and the potential commercial value of vaccines based on the mRNA technology route is huge.
In the future, the company can better apply this technology to the development of other vaccines.
At the same time, the company’s rich R&D pipeline is also very good.
Support the company's products to go global and enhance the voice and competitiveness in the global biopharmaceutical market.
According to the industry, Fosun Pharma has achieved today's results precisely because of its years of accumulation of internationalization and its insistence on innovative research and development concepts.

Internationalization is the development trend of the pharmaceutical industry in the future.
It is understood that domestic pharmaceutical companies have been active in licensing transactions this year, especially the increase in cooperation with multinational pharmaceutical companies.
The ability to license and authorize multinational pharmaceutical companies also shows the R&D of these domestic pharmaceutical companies.
Capabilities and products have reached the international frontier level, and have the potential to move towards internationalization.
In addition to licensing transactions, domestic pharmaceutical companies have also made great progress in overseas clinical trials.
Among them, the global multi-center clinical trials of some products such as BeiGene, Kanghong, Corning Jerry, and Yasheng have also gradually entered Phase III.

According to the industry, medical insurance negotiations have changed the business model of domestic innovative drugs and the drug life cycle to a certain extent.
Since the new round of medical reform in 2009 and the establishment of the National Medical Insurance Agency in 2018, the pharmaceutical industry and capital markets have increasingly discussed the sustainability of the domestic universal medical insurance-based payment system in the medium and long-term dimensions, and the industry has gradually formed There is a consensus-"It is not enough to only earn domestic money, we still have to go out to earn overseas money.
"

Looking back at the development of my country’s pharmaceutical industry in the past 20 years, the size of pharmaceutical terminals has increased from 157.
2 billion in 2000 to 1.
71 trillion in 2018.
This is accompanied by an increase in my country’s medical insurance expenditure from 12.
5 billion to 1.
76 trillion.
To some extent, the ability to pay Determines the development space of the industry.
Therefore, only by moving to the internationally regulated market and developing products with global pricing value can the ceiling of corporate income be truly opened.

In addition, some people in the industry said, “We understand the industry’s longing for or expectation for internationalization, but we don’t really expect how much income and profit we can earn from overseas in the short term, but we hope that companies can form a certain global competitiveness, especially the pharmaceutical industry itself.
It’s the global market.
.
.
"

In short, whether it is to realize the abbreviated internationalization of a single product through license out, or to integrate R&D registration and the full internationalization of the sales industry chain, these are all beneficial explorations for the industry.
"We believe that in the next 5-10 years, 3-5 pharmaceutical companies will become truly Chinese MNC companies.
" An insider said.